Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
10x Genomics Analyst Ratings and Price Targets | NASDAQ:TXG | Benzinga
10x Genomics Inc has a consensus price target of $23.85 based on the ratings of 20 analysts. The high is $60 issued by Goldman Sachs on July 14, 2022. The low is $6.5 issued by Goldman Sachs on May 12, 2025. The 3 most-recent analyst ratings were released by Barclays, Morgan Stanley, and Stephens & Co. on June 24, 2025, May 19, 2025, and May 15, 2025, respectively. With an average price target of $15 between Barclays, Morgan Stanley, and Stephens & Co., there's an implied 37.23% upside for 10x Genomics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Morgan Stanley
Stephens & Co.
UBS
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for 10x Genomics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2025 | Buy Now | 18.93% | Barclays | Luke Sergott51% | $12 → $13 | Maintains | Overweight | Get Alert |
| 05/19/2025 | Buy Now | 64.67% | Morgan Stanley | Tejas Savant51% | $26 → $18 | Maintains | Overweight | Get Alert |
| 05/15/2025 | Buy Now | 28.08% | Stephens & Co. | Mason Carrico43% | $14 → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 05/13/2025 | Buy Now | 9.78% | UBS | Dan Leonard55% | $14 → $12 | Maintains | Neutral | Get Alert |
| 05/12/2025 | Buy Now | -40.53% | Goldman Sachs | Matthew Sykes64% | $7.5 → $6.5 | Maintains | Sell | Get Alert |
| 05/12/2025 | Buy Now | 37.23% | Canaccord Genuity | Kyle Mikson41% | $18 → $15 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | -17.66% | JP Morgan | Rachel Vatnsdal65% | $12 → $9 | Maintains | Neutral | Get Alert |
| 04/10/2025 | Buy Now | 9.78% | Barclays | Luke Sergott51% | $15 → $12 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | 37.23% | Citigroup | Patrick Donnelly80% | $20 → $15 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | 137.86% | Morgan Stanley | Tejas Savant51% | $28 → $26 | Maintains | Overweight | Get Alert |
| 02/14/2025 | Buy Now | 37.23% | Barclays | Luke Sergott51% | $18 → $15 | Maintains | Overweight | Get Alert |
| 02/13/2025 | Buy Now | 64.67% | Canaccord Genuity | Kyle Mikson41% | $20 → $18 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 82.97% | Citigroup | Patrick Donnelly80% | $23 → $20 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 9.78% | JP Morgan | Rachel Vatnsdal65% | $14 → $12 | Maintains | Neutral | Get Alert |
| 02/13/2025 | Buy Now | 28.08% | UBS | Dan Leonard55% | $20 → $14 | Maintains | Neutral | Get Alert |
| 02/13/2025 | Buy Now | 64.67% | Stifel | Daniel Arias78% | $21 → $18 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 9.78% | Leerink Partners | Mike Kratky66% | $25 → $12 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/10/2025 | Buy Now | 64.67% | Barclays | Luke Sergott51% | $19 → $18 | Maintains | Overweight | Get Alert |
| 01/13/2025 | Buy Now | 156.16% | Morgan Stanley | Tejas Savant51% | $30 → $28 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 73.82% | Barclays | Luke Sergott51% | $21 → $19 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 110.42% | Citigroup | Patrick Donnelly80% | $35 → $23 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 28.08% | Goldman Sachs | Matthew Sykes64% | $16 → $14 | Maintains | Sell | Get Alert |
| 10/30/2024 | Buy Now | 28.08% | JP Morgan | Rachel Vatnsdal65% | $20 → $14 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | 82.97% | UBS | Dan Leonard55% | $25 → $20 | Maintains | Neutral | Get Alert |
| 10/15/2024 | Buy Now | 92.12% | Barclays | Luke Sergott51% | $24 → $21 | Maintains | Overweight | Get Alert |
| 10/10/2024 | Buy Now | 174.46% | Stephens & Co. | Mason Carrico43% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 10/10/2024 | Buy Now | 82.97% | Canaccord Genuity | Kyle Mikson41% | $32 → $20 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | 174.46% | Stephens & Co. | Mason Carrico43% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 09/03/2024 | Buy Now | 220.2% | Leerink Partners | Mike Kratky66% | → $35 | Initiates | → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 128.71% | UBS | Dan Leonard55% | $30 → $25 | Maintains | Neutral | Get Alert |
| 08/13/2024 | Buy Now | 320.83% | Morgan Stanley | Tejas Savant51% | $50 → $46 | Maintains | Overweight | Get Alert |
| 07/23/2024 | Buy Now | 192.75% | Canaccord Genuity | Kyle Mikson41% | $50 → $32 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 119.57% | Jefferies | Tycho Peterson82% | $24 → $24 | Upgrade | Hold → Buy | Get Alert |
| 07/18/2024 | Buy Now | 128.71% | B of A Securities | Derik De Bruin84% | $36 → $25 | Maintains | Neutral | Get Alert |
| 07/18/2024 | Buy Now | 82.97% | JP Morgan | Rachel Vatnsdal65% | $40 → $20 | Downgrade | Overweight → Neutral | Get Alert |
| 07/16/2024 | Buy Now | 128.71% | Stifel | Daniel Arias78% | $53 → $25 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 128.71% | Deutsche Bank | Justin Bowers47% | $55 → $25 | Downgrade | Buy → Hold | Get Alert |
| 07/09/2024 | Buy Now | 46.38% | Goldman Sachs | Matthew Sykes64% | $26 → $16 | Maintains | Sell | Get Alert |
| 06/28/2024 | Buy Now | 119.57% | Barclays | Luke Sergott51% | $36 → $24 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | — | Wolfe Research | Doug Schenkel72% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 06/26/2024 | Buy Now | — | Guggenheim | Subbu Nambi48% | — | Downgrade | Buy → Neutral | Get Alert |
| 06/25/2024 | Buy Now | — | Guggenheim | Subbu Nambi48% | — | Downgrade | Buy → Neutral | Get Alert |
| 06/03/2024 | Buy Now | 119.57% | Jefferies | Tycho Peterson82% | → $24 | Initiates | → Hold | Get Alert |
| 05/01/2024 | Buy Now | 174.46% | UBS | Dan Leonard55% | $52 → $30 | Maintains | Neutral | Get Alert |
| 05/01/2024 | Buy Now | 229.35% | B of A Securities | Derik De Bruin84% | $45 → $36 | Maintains | Neutral | Get Alert |
| 05/01/2024 | Buy Now | 137.86% | Goldman Sachs | Matthew Sykes64% | $30 → $26 | Maintains | Sell | Get Alert |
| 05/01/2024 | Buy Now | 192.75% | TD Cowen | Dan Brennan63% | $57 → $32 | Downgrade | Buy → Hold | Get Alert |
| 05/01/2024 | Buy Now | 384.87% | Stifel | Daniel Arias78% | $63 → $53 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 357.43% | Canaccord Genuity | Kyle Mikson41% | $65 → $50 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 403.17% | Deutsche Bank | Justin Bowers47% | $60 → $55 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 311.68% | Barclays | Luke Sergott51% | $55 → $45 | Maintains | Overweight | Get Alert |
| 02/16/2024 | Buy Now | 476.36% | Stifel | Daniel Arias78% | $68 → $63 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | 403.17% | Barclays | Luke Sergott51% | $45 → $55 | Maintains | Overweight | Get Alert |
| 12/14/2023 | Buy Now | 448.91% | Guggenheim | Subbu Nambi48% | → $60 | Initiates | → Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel72% | — | Initiates | → Outperform | Get Alert |
| 12/12/2023 | Buy Now | 394.02% | B of A Securities | Derik De Bruin84% | $36 → $54 | Upgrade | Underperform → Neutral | Get Alert |
| 09/29/2023 | Buy Now | 329.98% | Barclays | Luke Sergott51% | $66 → $47 | Maintains | Overweight | Get Alert |
| 09/19/2023 | Buy Now | 540.4% | Canaccord Genuity | Kyle Mikson41% | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 494.66% | Morgan Stanley | Tejas Savant51% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 503.8% | Barclays | Luke Sergott51% | $65 → $66 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 586.14% | Citigroup | Patrick Donnelly80% | $65 → $75 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | 174.46% | Goldman Sachs | Matthew Sykes64% | $25 → $30 | Maintains | Sell | Get Alert |
| 05/18/2023 | Buy Now | 494.66% | Stephens & Co. | Mason Carrico43% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2023 | Buy Now | 494.66% | Barclays | Luke Sergott51% | → $65 | Initiates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 522.1% | Stifel | Daniel Arias78% | $57 → $68 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 503.8% | TD Cowen | Dan Brennan63% | $62 → $66 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | 494.66% | Canaccord Genuity | Kyle Mikson41% | $58 → $65 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 494.66% | Stephens & Co. | Mason Carrico43% | → $65 | Reiterates | → Overweight | Get Alert |
| 03/31/2023 | Buy Now | 494.66% | Stephens & Co. | Mason Carrico43% | → $65 | Initiates | → Overweight | Get Alert |
| 02/16/2023 | Buy Now | 494.66% | Morgan Stanley | Tejas Savant51% | $64 → $65 | Maintains | Overweight | Get Alert |
| 02/16/2023 | Buy Now | 430.62% | Canaccord Genuity | Kyle Mikson41% | $55 → $58 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | 421.47% | Cowen & Co. | Dan Brennan63% | $52 → $57 | Maintains | Outperform | Get Alert |
| 02/02/2023 | Buy Now | 357.43% | UBS | John Sourbeer32% | → $50 | Initiates | → Neutral | Get Alert |
| 12/14/2022 | Buy Now | 357.43% | Deutsche Bank | Justin Bowers47% | → $50 | Initiates | → Buy | Get Alert |
| 11/04/2022 | Buy Now | 485.51% | Morgan Stanley | Tejas Savant51% | $70 → $64 | Maintains | Overweight | Get Alert |
| 10/13/2022 | Buy Now | 128.71% | Goldman Sachs | Matthew Sykes64% | $35 → $25 | Maintains | Sell | Get Alert |
| 08/18/2022 | Buy Now | 220.2% | Goldman Sachs | Matthew Sykes64% | $55 → $35 | Downgrade | Neutral → Sell | Get Alert |
| 08/10/2022 | Buy Now | 540.4% | Morgan Stanley | Tejas Savant51% | $100 → $70 | Maintains | Overweight | Get Alert |
| 07/15/2022 | Buy Now | 357.43% | Cowen & Co. | Dan Brennan63% | $90 → $50 | Maintains | Outperform | Get Alert |
| 07/15/2022 | Buy Now | 220.2% | B of A Securities | Derik De Bruin84% | $80 → $35 | Downgrade | Neutral → Underperform | Get Alert |
| 07/15/2022 | Buy Now | — | William Blair | Brian Weinstein27% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/14/2022 | Buy Now | 448.91% | Goldman Sachs | Amit Hazan56% | $80 → $60 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for 10x Genomics (TXG) stock?
The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Barclays on June 24, 2025. The analyst firm set a price target for $13.00 expecting TXG to rise to within 12 months (a possible 18.93% upside). 42 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 10x Genomics (TXG)?
The latest analyst rating for 10x Genomics (NASDAQ:TXG) was provided by Barclays, and 10x Genomics maintained their overweight rating.
When was the last upgrade for 10x Genomics (TXG)?
The last upgrade for 10x Genomics Inc happened on July 22, 2024 when Jefferies raised their price target to $24. Jefferies previously had a hold for 10x Genomics Inc.
When was the last downgrade for 10x Genomics (TXG)?
The last downgrade for 10x Genomics Inc happened on February 13, 2025 when Leerink Partners changed their price target from $25 to $12 for 10x Genomics Inc.
When is the next analyst rating going to be posted or updated for 10x Genomics (TXG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on June 24, 2025 so you should expect the next rating to be made available sometime around June 24, 2026.
Is the Analyst Rating 10x Genomics (TXG) correct?
While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $12.00 to $13.00. The current price 10x Genomics (TXG) is trading at is $10.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
